INO-A002 / Inovio - LARVOL DELTA

A Study of INO-A002 in Healthy Dengue Virus-naive Adults (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: University of Pennsylvania | Active, not recruiting ➔ Completed

Trial completion • Dengue Fever • CD4

A Study of INO-A002 in Healthy Dengue Virus-naive Adults (clinicaltrials.gov) - P1; N=30; Active, not recruiting; Sponsor: University of Pennsylvania; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Dengue Fever • CD4

A Study of INO-A002 in Healthy Dengue Virus-naive Adults (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: University of Pennsylvania; Trial completion date: Feb 2023 ➔ Oct 2022; Trial primary completion date: Feb 2023 ➔ Oct 2022

Clinical • Trial completion date • Trial primary completion date • Dengue Fever • CD4

A Study of INO-A002 in Healthy Dengue Virus-naive Adults (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: University of Pennsylvania; Active, not recruiting ➔ Recruiting

Clinical • Enrollment open • Dengue Fever • CD4

A Study of INO-A002 in Healthy Dengue Virus-naive Adults (clinicaltrials.gov) - P1; N=24; Active, not recruiting; Sponsor: University of Pennsylvania; Trial completion date: Feb 2021 ➔ Feb 2023; Trial primary completion date: Feb 2021 ➔ Feb 2023

Clinical • Trial completion date • Trial primary completion date • Dengue Fever • CD4

A Study of INO-A002 in Healthy Dengue Virus-naive Adults (clinicaltrials.gov) - P1; N=24; Active, not recruiting; Sponsor: University of Pennsylvania; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed